Clinical Trial Update: A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA Nephropathy [Phase 2]

View source ↗

Summary

Phase IIa clinical study of RG002C0106 injection for IgA nephropathy is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iga Nephropathy

Drugs mentioned

• RG002C0106 injection (RG002C0106)

Snippet

Sponsor: Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd. | Conditions: IgA Nephropathy (IgAN) | Phase 2 | Status: RECRUITING